Market
Novo Nordisk's market share change post-Catalent acquisition by 2025
2
Resolution / Starting Odds
Increase by more than 5% • 25%
Increase by 1-5% • 25%
No significant change • 25%
Decrease • 25%
Market analysis reports from financial analysts or market research firms
Story
Novo Nordisk Cleared to Acquire Three Catalent Manufacturing Sites for $CTLT Following FTC Approval
Dec 14, 2024, 08:49 AM
Novo Nordisk has received clearance to proceed with its acquisition of three manufacturing sites from Catalent, following the Federal Trade Commission's decision not to challenge the deal. This acquisition is part of a larger transaction involving Catalent and Novo Holdings, which has also met all regulatory closing conditions. The approval allows Novo Nordisk to enhance its manufacturing capabilities by integrating these sites, thereby strengthening its position in the pharmaceutical sector. The deal has been noted as significant given the current regulatory environment surrounding pharmaceutical acquisitions.
View original story
Similar markets
No change • 25%
Decrease • 25%
Slightly increase • 25%
Significantly increase • 25%
Outperform significantly • 25%
Underperform • 25%
Outperform slightly • 25%
Match performance • 25%
Less than 5% • 25%
More than 15% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 50% • 25%
Less than 30% • 25%
30% to 40% • 25%
40% to 50% • 25%
Significant increase • 25%
Moderate increase • 25%
No significant change • 25%
Decrease • 25%
Discontinue development • 25%
Partner with another company • 25%
Seek further trials • 25%
Submit for regulatory approval • 25%
Increase by more than 10% • 25%
Decrease by 0-10% • 25%
Decrease by more than 10% • 25%
Increase by 0-10% • 25%